Inaba H

Language: English
References: 13
Page: 91-94
PDF size: 369.82 Kb.

ABSTRACT

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. The current approach to treating ALL uses risk stratification based on the biological features of the leukemic cells and the response to treatment. However, to further improve survival to as close to 100% as possible and to reduce the adverse effects of treatment, innovative approaches are needed. Currently, many frontline ALL treatment protocols are incorporating novel precision-medicine strategies based on inherited and leukemia/ lymphoma-specific genomic features and targeted treatment approaches, which could lead to improved cure rates and reduced toxicities.

REFERENCES

1. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730-41.

2. Inaba H, Greaves M, Mullighan CG: Acute lymphoblastic leukaemia. Lancet 2013;381:1943-55.

3. Inaba H, Azzato EM, Mullighan CG. Integration of nextgeneration sequencing to treat acute lymphoblastic leukemia with targetable lesions: the St. Jude Children’s Research Hospital approach. Front Pediatr 2017;5:258.

4. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-49.

5. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006;6:193-203.

6. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373:1541-52.

7. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinaseactivating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371:1005-15.

8. van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015;125:3996-4009.

9. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439-48.

10. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836-47.

11. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740-53.

12. Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015;313:815-23.

13. Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015;33:1235-42.